Kidney transplantation – be aware of TCC

Plasma TCC (sC5b-9) is associated with both patient and kidney long-time survival.

 

Nephrologists from aHUS and OUS Rikshospitalet have together with complementologists from NCRG recently presented data in Front Immunol showing data in 900 patients over a 10-year period that increased plasma TCC levels obtained in a stable period at 10 weeks after transplantation  was associated with  patient survival, graft survival and  with death-censored graft loss.

Plasma TCC has again strengthened its position as an important marker in disease pathophysiology, adding another possible indication for complement therapeutic in the future.

Bartlomiej J. Witczak and Søren E. Pieschke were 1st and 2nd authors, and Anders Åsberg and Tom E. Mollnes shared the last authorship.

Here is the link to all authors and the paper – released by Frontiers and will soon be available on PuMed:

Frontiers | Elevated Terminal C5b-9 Complement Complex 10 Weeks Post Kidney Transplantation Was Associated With Reduced Long-Term Patient and Kidney Graft Survival | Immunology (frontiersin.org)

 

Scroll Up

Similar News

Dissemination

Novel mechanism of selective C3 activation by air bubbles

Benjamin S. Storm and collaborators in J Immunology   A breaking news paper was released on PubMed November 3rd published...

Read more
Dissemination

Abstract price

Price for abstract at the Norwegian Annual Meeting for Anaesthesiology   At the meeting held in Tromsø recently, Andreas Barratt-Due...

Read more
Dissemination
Mollnes, Tom Eirik Aug 18. 2021.

Thrombin does NOT cleave C5 under physiological conditions

A novel whole blood model revealed that thrombin does not cleave native C5. Selected by the J Immunol Editor as...

Read more